Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Marina C, Garassino"'
Autor:
Divya Choudhury, James M. Dolezal, Emma Dyer, Sara Kochanny, Siddhi Ramesh, Frederick M. Howard, Jayson R. Margalus, Amelia Schroeder, Jefree Schulte, Marina C. Garassino, Jakob N. Kather, Alexander T. Pearson
Publikováno v:
EBioMedicine, Vol 107, Iss , Pp 105276- (2024)
Summary: Background: Deployment and access to state-of-the-art precision medicine technologies remains a fundamental challenge in providing equitable global cancer care in low-resource settings. The expansion of digital pathology in recent years and
Externí odkaz:
https://doaj.org/article/8abddce9a56d4c5aa460bd06647693f0
Autor:
Marina C. Garassino, MD, Sabine Oskar, PhD, MPH, Ashwini Arunachalam, MPH, BDS, Ke Zu, PhD, ScD, MPH, Yu-Han Kao, PhD, Cai Chen, PhD, Weilin Meng, MEng, M. Catherine Pietanza, MD, Bin Zhao, MD, Himani Aggarwal, MPhil, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 10, Pp 100568- (2023)
Introduction: Data on utilization and clinical outcomes of programmed cell death protein or programmed death-ligand 1 (PD-[L]1) inhibitors in NSCLC with uncommon oncogenic alterations is limited. Methods: This retrospective study used a deidentified
Externí odkaz:
https://doaj.org/article/1969648679be4785880ac7e95d565f5e
Autor:
Robert B. Cameron, Jacobi B. Hines, Valter Torri, Luca Porcu, Jessica Donington, Christine M. Bestvina, Everett Vokes, James M. Dolezal, Alessandra Esposito, Marina C. Garassino
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Numerous clinical trials investigating neoadjuvant immune checkpoint inhibitors (ICI) have been performed over the last 5 years. As the number of neoadjuvant trials increases, attention must be paid to identifying informative trial endpoints. Complet
Externí odkaz:
https://doaj.org/article/68f1ae4490e14171883a3791e16df353
Autor:
Marina C. Garassino, MD, Shirish Gadgeel, MD, Silvia Novello, MD, PhD, Balazs Halmos, MD, Enriqueta Felip, MD, Giovanna Speranza, MD, Rina Hui, PhD, Edward B. Garon, MD, Hidehito Horinouchi, MD, PhD, Shunichi Sugawara, MD, PhD, Delvys Rodriguez-Abreu, MD, PhD, Martin Reck, MD, Razvan Cristescu, PhD, Deepti Aurora-Garg, PhD, Andrey Loboda, PhD, Jared Lunceford, PhD, Julie Kobie, PhD, Mark Ayers, MS, Bilal Piperdi, MD, M. Catherine Pietanza, MD, Luis Paz-Ares, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 1, Pp 100431- (2023)
Introduction: We evaluated tissue tumor mutational burden (tTMB) and mutations in STK11, KEAP1, and KRAS as biomarkers for outcomes with pembrolizumab plus platinum-based chemotherapy (pembrolizumab-combination) for NSCLC among patients in the phase
Externí odkaz:
https://doaj.org/article/5b31e33aa86a4148993ed9fca9e915ac
Autor:
Annalisa Trama, Claudia Proto, Diego Signorelli, Marina C. Garassino, Giuseppe Lo Russo, Monica Ganzinelli, Arsela Prelaj, Carolina Mensi, Manuela Gangemi, Valerio Gennaro, Elisabetta Chellini, Adele Caldarella, Italo F. Angelillo, Valeria Ascoli, Cristiana Pascucci, Giovanna Tagliabue, Rosanna Cusimano, Francesca Bella, Fabio Falcini, Enzo Merler, Giuseppe Masanotti, Antonio Ziino, Maria Michiara, Gemma Gola, Cinzia Storchi, Lucia Mangone, Maria F. Vitale, Claudia Cirilli, Rosario Tumino, Tiziana Scuderi, Anna C. Fanetti, Silvano Piffer, Marcello Tiseo, Gemma Gatta, Laura Botta, the LUME study WG
Publikováno v:
Thoracic Cancer, Vol 11, Iss 6, Pp 1661-1669 (2020)
Abstract Background Malignant pleural mesothelioma (MPM) is a rare cancer with a poor prognosis. Centralization of rare cancer in dedicated centers is recommended to ensure expertise, multidisciplinarity and access to innovation. In Italy, expert cen
Externí odkaz:
https://doaj.org/article/02f86e80f4c448e49c3063f248286927
Autor:
Misha C. Tran, Garth W. Strohbehn, Theodore G. Karrison, Sherin J. Rouhani, Jeremy P. Segal, Ardaman Shergill, Philip C. Hoffman, Jyoti D. Patel, Marina C. Garassino, Everett E. Vokes, Christine M. Bestvina
Publikováno v:
Clinical Lung Cancer. 24:e117-e121
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::16641b0206eeb48ca714ee08220bc5fe
https://doi.org/10.1016/j.cllc.2023.01.003
https://doi.org/10.1016/j.cllc.2023.01.003
Autor:
Marina C. Garassino, Shirish Gadgeel, Giovanna Speranza, Enriqueta Felip, Emilio Esteban, Manuel Dómine, Maximilian J. Hochmair, Steven F. Powell, Helge G. Bischoff, Nir Peled, Francesco Grossi, Ross R. Jennens, Martin Reck, Rina Hui, Edward B. Garon, Takayasu Kurata, Jhanelle E. Gray, Paul Schwarzenberger, Erin Jensen, M. Catherine Pietanza, Delvys Rodríguez-Abreu
Publikováno v:
Scientia
Pembrolizumab; Non-small-cell lung cancer Pembrolizumab; Cáncer de pulmón de células no pequeñas Pembrolizumab; Càncer de pulmó de cèl·lules no petites Clinical trials frequently include multiple end points that mature at different times. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::374e74c86ca13e92597e504ff2706d68
https://doi.org/10.1200/jco.22.01989
https://doi.org/10.1200/jco.22.01989
Autor:
Adele Busico, Valter Torri, Giulia Galli, Giuseppe Lo Russo, Claudia Proto, Monica Ganzinelli, Claudio Vernieri, Diego Signorelli, Eliana Rulli, Gabriella Farina, Anna Cecilia Bettini, Claudia Bareggi, Lorenzo Rosso, Massimo Moro, Stefano Indraccolo, Gabriella Sozzi, Mirko Marabese, Broggini Massimo, Marina C. Garassino
Publikováno v:
ESMO Open, Vol 5, Iss 3 (2020)
Purpose In patients with advanced lung adenocarcinoma, the impact of LKB1 mutations on cytotoxic chemotherapy efficacy remains poorly explored. Here, we aimed at investigating the potential impact of LKB1 mutational status on chemotherapy efficacy in
Externí odkaz:
https://doaj.org/article/ad478f6cb06d4da4bde645cde55f4aaf
Autor:
Elisa Caiola, Francesca Falcetta, Silvia Giordano, Mirko Marabese, Marina C. Garassino, Massimo Broggini, Roberta Pastorelli, Laura Brunelli
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 37, Iss 1, Pp 1-14 (2018)
Abstract Background Non–small-cell lung cancer (NSCLC) is a heterogeneous disease, with multiple different oncogenic mutations. Approximately 25–30% of NSCLC patients present KRAS mutations, which confer poor prognosis and high risk of tumor recu
Externí odkaz:
https://doaj.org/article/474da9b03393471187ac6728435107d0
Autor:
Divya Choudhury, James Dolezal, Emma Dyer, Sara Kochanny, Siddi Ramesh, Frederick M. Howard, Jayson R. Margalus, Amelia Schroeder, Jefree Schulte, Marina C. Garassino, Jakob N. Kather, Alexander T. Pearson
Deployment and access to state-of-the-art diagnostic technologies remains a fundamental challenge in providing equitable global cancer care to low-resource settings. The expansion of digital pathology in recent years and its interface with computatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::28371c72780a04a3ea6d872b08e75445
https://doi.org/10.1101/2023.04.19.537544
https://doi.org/10.1101/2023.04.19.537544
